Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy December 10, 2025 8:30 AM EST
Company Participants
Fahar Merchant - Founder, Chairman, President & CEO Hussein Tawbi Paolo Ascierto
Conference Call Participants
Arash Yavari - Imbria Pharmaceuticals, Inc. André Mansinho Igor Puzanov Toni Choueiri - Precede Biosciences, Inc. David Martin - Bloom Burton & Co., Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Kambiz Yazdi - BTIG, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research …
Medicenna Therapeutics Corp. (MDNA:CA) Discusses New Clinical Data From ABILITY-1 Study Evaluating MDNA11 in Cancer Immunotherapy December 10, 2025 8:30 AM EST
Company Participants
Fahar Merchant - Founder, Chairman, President & CEO Hussein Tawbi Paolo Ascierto
Conference Call Participants
Arash Yavari - Imbria Pharmaceuticals, Inc. André Mansinho Igor Puzanov Toni Choueiri - Precede Biosciences, Inc. David Martin - Bloom Burton & Co., Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Kambiz Yazdi - BTIG, LLC, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Welcome to Medicenna Therapeutics KOL Webinar. [Operator Instructions] As a reminder, this conference call is being recorded. If you have any objections, please disconnect at this time. I’d now like to turn the call over to Dr. Fahar Merchant, President and CEO.
Fahar Merchant Founder, Chairman, President & CEO
Good morning, good afternoon, everyone, and thank you for joining us today. My name is Dr. Fahar Merchant, President and CEO of Medicenna Therapeutics. We are thrilled to welcome you to this exclusive webinar as we discuss exciting new clinical data from our ABILITY-1 study evaluating MDNA11. Before we begin, I’d like to remind everyone that this webinar contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may be identified by the use of words such as believe, may, will, continue, anticipate, intend, expect, should, would, could, plan, potential, promise and similar expressions. These forward-looking statements are subject to risks and uncertainties, including, but not limited to the risks inherent in clinical drug development, regulatory approval processes, competitive factors and other risks described in Medicenna’s filings with the Securities and Exchange Commission and Applicable Canadian Securities regulators.
Actual results may differ materially from those expressed or implied by forward-looking statements Medicenna disclaims any obligation to update these forward-looking statements, except as required by law. For